- Home
- NRDS vs PHAT Comparison
NRDS vs PHAT Comparison
Compare NRDS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | PHAT |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 942.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NRDS | PHAT |
|---|---|---|
| Price | $13.76 | $15.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $15.83 | ★ $17.33 |
| AVG Volume (30 Days) | 777.2K | ★ 911.3K |
| Earning Date | 02-18-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $795,000,000.00 | $147,190,000.00 |
| Revenue This Year | $22.09 | $220.37 |
| Revenue Next Year | $7.18 | $83.14 |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | 24.71 | ★ 460.30 |
| 52 Week Low | $7.55 | $2.21 |
| 52 Week High | $16.24 | $18.31 |
Technical Indicators
Market Signals| Indicator | NRDS | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 47.30 |
| Support Level | $12.83 | $15.43 |
| Resistance Level | $14.05 | $18.09 |
| Average True Range (ATR) | 0.41 | 0.91 |
| MACD | -0.09 | -0.13 |
| Stochastic Oscillator | 40.65 | 12.66 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.